Breaking News, Collaborations & Alliances

Rexahn & BioSense Enter License Agreement

To advance the development and commercialization of RX-3117 for pancreatic cancer and other cancers in Greater China

Rexahn Pharmaceuticals and BioSense Global announced a collaboration and license agreement to advance the development and commercialization of RX-3117 for pancreatic cancer and other cancers in Greater China. Under the agreement, Rexahn will grant BioSense an exclusive license to develop and commercialize RX-3117 in Greater China. Rexahn will receive an upfront payment and will be eligible to receive additional development, regulatory and commercial milestones up to a total of $226 millio...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters